摘要
目的:探讨三维适形放疗联合替吉奥与奈达铂同步化疗治疗局部晚期食管癌的近期疗效及毒副反应。方法:对我科自2010年9月至2011年6月收治的60例符合入组条件的食管癌患者随机分为2组,所有患者均采用三维适形放射治疗技术,常规分割,总剂量60-66Gy,6-7周完成放疗计划。同步化疗组给予替吉奥80mg/m2,d1-d14,奈达铂90mg/m2,d1,每4周重复。结果:1例失访,59例可评价疗效及毒副反应。随访时间至放疗结束后3月。同步化疗及单纯放疗组RR(PR+CR)分别为86.2%,63.3%,差异具有统计学意义。主要毒副反应为骨髓抑制及放射性食管炎。毒副反应同步化疗组较单纯放疗组多见,经积极处理所有患者均完成治疗计划。结论:三维适形放疗联合替吉奥与奈达铂同步化疗治疗局部晚期食管癌较单纯放疗近期疗效显著提高,毒副反应可以耐受,该方案的远期效果有待进一步观察。
Objective：To evaluate the efficacy and safety of nedaplatin plus S-1 and combined with synchronous three-dimensional conformal radiotherapy in the treatment of mediumterm and terminal esophageal cancer.Methods：Between September 2010 and June 2011,60 patients with advanced squamous cell carcinoma of the esophagus were divided into two groups：group RT（30 cases） and group CRT（30 cases）.Three-dimensional conformal radiotherapy was administered in all cases,with a total dose of（60-66）Gy/（30-33）fx,conventional fractionation.Group CRT was given S-1 80mg/m^2 on days 1-14,and nedaplatin 90 mg/m^2 on day 1 every 4 weeks.Results：Of 60 patients in this trial,the response and toxicity of 59 cases were available to be evaluated.The overall response rate（PR＋CR） of group RT and group CRT were 63.3% and 86.2% respectively after 3 months of follow up.（P〈0.05）The main toxicities were marrow depression and radioactive esophagitis.The CRT patients had more toxicities and all of them complete treating plan.Conclusion：The short-term curative effect of S-1 and nedaplatin in combination with radiotherapy is feasible for medium-term and terminal esophageal cancer,and toxicity is tolerable.
出处
《现代肿瘤医学》
CAS
2012年第11期2283-2286,共4页
Journal of Modern Oncology
基金
南京军区南京总医院青年基金项目(编号:2009Q051)
关键词
食管癌
替吉奥胶囊
奈达铂
三维适形放疗
esophageal
S-1
nedaplatin
three-dimensional conformal radiotherapy
